CEB-01 is under clinical development by Cebiotex and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData, Phase I drugs for Soft Tissue Sarcoma have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CEB-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CEB-01 overview
CEB-01 is under development for the treatment of leiomyosarcoma, liposarcoma, pleomorphic liposarcoma, nerve sheath tumor, solid tumors including neuroblastoma and Ewing sarcoma in pediatrics and surgical beds of soft tissue sarcoma in pediatrics and adults. It is developed based on nanofiber engineering technology that enables the production of non-woven nanofiber membranes, for the controlled release of therapeutic agents for the local treatment of unresectable tumors.
Cebiotex overview
Cebiotex provides manufacturing technology and contract research solutions. The company concentrates offers development of electrospun nanofiber technologies and nanofiber products. It provide nonwoven nanofiber membranes for the controlled release of active agents that helps in the treatment of unresectable tumors. Cebiotex’s nanofibre engineering technology is used for the production of nonwoven nanofiber membranes based on optimized electrospinning process. The company offers manufacturing technology and contract research in the field of drug delivery. It collaborates with biotech companies and research universities for its research and development activities. Cebiotex is headquartered in Barcelona, Spain.
For a complete picture of CEB-01’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
